DAEWON PHARMACEUTICAL CO.,LTD
003220 | KO
Overview
Corporate Details
- ISIN(s):
- KR7003220001
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 성동구 천호대로 386 대원제약, 서울특별시
- Website:
- https://www.daewonpharm.com/eng
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-17 00:00 |
Regulatory Filings
[기재정정]투자판단관련주요경영사항 (코대원플러스정 식품의약품안전처 국내 품목허가 신청)
|
Korean | 24.0 KB | ||
| 2025-09-09 00:00 |
Transaction in Own Shares
자기주식처분결과보고서
|
Korean | 19.3 KB | ||
| 2025-09-09 00:00 |
Share Issue/Capital Change
유상증자또는주식관련사채등의발행결과(자율공시)
|
Korean | 6.0 KB | ||
| 2025-09-02 00:00 |
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
|
Korean | 34.4 KB | ||
| 2025-09-02 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
|
Korean | 31.4 KB | ||
| 2025-08-29 00:00 |
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
|
Korean | 16.5 KB | ||
| 2025-08-25 00:00 |
Share Issue/Capital Change
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
|
Korean | 13.7 KB | ||
| 2025-08-19 00:00 |
Share Issue/Capital Change
[기재정정]감자결정(종속회사의주요경영사항)
|
Korean | 20.0 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 2.7 MB | ||
| 2025-08-12 00:00 |
Share Issue/Capital Change
감자결정(종속회사의주요경영사항)
|
Korean | 16.1 KB | ||
| 2025-06-02 00:00 |
Governance Information
기업지배구조보고서공시
|
Korean | 946.4 KB | ||
| 2025-05-30 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (코대원플러스정 식품의약품안전처 국내 품목허가 신청)
|
Korean | 10.9 KB | ||
| 2025-05-23 00:00 |
Share Issue/Capital Change
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
|
Korean | 13.2 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 2.3 MB | ||
| 2025-04-30 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (DW4421 제3상 임상시험계획 승인신청(미란성))
|
Korean | 8.4 KB |
Automate Your Workflow. Get a real-time feed of all DAEWON PHARMACEUTICAL CO.,LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for DAEWON PHARMACEUTICAL CO.,LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DAEWON PHARMACEUTICAL CO.,LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops & commercializes anti-infectives for severe bacterial & fungal infections.
Switzerland
BSLN
Switzerland
BSLN
Develops, manufactures, and markets pharmaceuticals, OTCs, and medical devices globally.
United States of America
BHC
United States of America
BHC
A global eye health company offering contact lenses, pharmaceuticals, and surgical devices for all.
United States of America
BLCO
United States of America
BLCO
A biotech firm developing and manufacturing life-saving vaccines for travel and public health.
Denmark
BAVA
Denmark
BAVA
Provides life-sustaining products for IV, surgical, and renal care in hospitals and homes.
United States of America
BAX
United States of America
BAX
A life science firm providing pharmaceuticals, consumer health, and crop science solutions.
Germany
BAY
Germany
BAY
Developed a bioactive bone graft substitute for orthopedic surgery before filing for bankruptcy.
Finland
BONE
Finland
BONE
Developing precision genetic medicines using base editing to provide cures for serious diseases.
United States of America
BEAM
United States of America
BEAM